CYTOPOINT 40 mg
LOKIVETMAB
What it does
Lokivetmab is a medication used to treat certain skin conditions in dogs, helping to reduce itching and inflammation.
Commonly used for: itchy skin (pruritus), atopic dermatitis
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: South African Health Products Regulatory Authority · fetched 2026-04-15 21:26:47 · updated 2026-09-23 04:12:19
About this medicine
Lokivetmab is a medication used to treat certain skin conditions in dogs, helping to reduce itching and inflammation.
What it treats
- itchy skin (pruritus)
- atopic dermatitis
How it works
Lokivetmab works by targeting and blocking a specific protein involved in the inflammatory response, which helps to alleviate itching and redness.
Who it's for
This medication is for dogs suffering from allergic skin conditions.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: lokivetmab
Lokivetmab is a monoclonal antibody specifically engineered to target and neutralize the activity of interleukin-31 (IL-31), a cytokine associated with pruritus (itching) in dogs. It is utilized as a therapeutic agent in veterinary medicine to alleviate itching and improve the quality of life in dogs suffering from allergic dermatitis, particularly atopic dermatitis.
Indications
- Atopic dermatitis in dogs
- Allergic dermatitis in dogs
Dosage
Children: Refer to specific veterinary guidelines as no standard paediatric dosage is provided.
Adults: Refer to specific veterinary guidelines as no standard adult dosage is provided.
Mechanism of action
Lokivetmab binds to interleukin-31 (IL-31) and inhibits its interaction with the IL-31 receptor, thus blocking the signaling pathways that lead to itching and inflammation. This effectively reduces the sensation of itch and the associated inflammatory response in the skin.
Pharmacodynamics
The pharmacodynamic effects of lokivetmab are primarily related to its ability to reduce pruritus and inflammation associated with allergic skin conditions in dogs. The action of lokivetmab helps in managing the symptoms of atopic dermatitis by directly targeting the pathway responsible for itch sensation.
Pharmacokinetics
Lokivetmab is administered subcutaneously and has a relatively long half-life, allowing for sustained action after administration. Due to its monoclonal antibody nature, it is expected to have limited oral bioavailability and is primarily eliminated via proteolytic degradation rather than through renal or hepatic pathways. The pharmacokinetics can vary based on factors such as the dog's weight and overall health.
Adverse effects
- Injection site reactions
- Vomiting
- Diarrhea
- Decreased appetite
- Lethargy
Precautions
- Use with caution in dogs with a history of allergic reactions
- Monitor for signs of adverse reactions post-administration
Pregnancy
The safety of lokivetmab during pregnancy has not been established.
Breast-feeding
The effects of lokivetmab during lactation are not well studied.
Storage
Store at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit). Do not freeze. Protect from light.
Formulations
- Injectable solution
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.